Cabaletta Bio Q2 2024 GAAP EPS $(0.56) Misses $(0.55) Estimate, Cash, Cash Equivalents And Short-term Investments Total $203.2M As Of June 30, 2024, Expected To Support Operations Into The First Half Of 2026
Portfolio Pulse from Benzinga Newsdesk
Cabaletta Bio reported a Q2 2024 GAAP EPS of $(0.56), missing the $(0.55) estimate. The company has $203.2M in cash, cash equivalents, and short-term investments as of June 30, 2024, which is expected to support operations into the first half of 2026.
August 08, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cabaletta Bio reported a Q2 2024 GAAP EPS of $(0.56), missing the $(0.55) estimate. The company has $203.2M in cash, cash equivalents, and short-term investments as of June 30, 2024, which is expected to support operations into the first half of 2026.
The EPS miss, although slight, is likely to have a negative short-term impact on the stock price. However, the strong cash position provides a cushion for future operations, which may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100